HUN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Huntsman Corp is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The stock is trading near $15, but the technical setup is only neutral-to-weak, analyst sentiment is mostly Hold/Neutral with mixed target changes, and the options flow is mildly bullish but not strong enough to override the lack of a clear breakout. My direct view: hold and wait for a better setup rather than buy now.
HUN is in a mixed short-term trend. MACD histogram is negative at -0.0461 and still below zero, though contracting, which suggests bearish momentum is fading but not yet reversed. RSI_6 at 64.2 is neutral to mildly constructive, and moving averages are converging, signaling a possible trend inflection but no confirmed uptrend. The key pivot is 14.712, with resistance at 15.31 and 15.68 and support at 14.115 and 13.745. At the pre-market price of 15, the stock is sitting just below first resistance, so upside is limited unless it breaks above 15.31.
["Deutsche Bank raised its price target to $15 from $14 and kept a Hold rating.", "Morgan Stanley raised its price target to $15 from $11, indicating improving valuation expectations.", "RBC said Q1 results and Q2 guidance topped estimates and price increases are being implemented ahead of rising raw material costs.", "The company sold its Gomet business for about $50 million to reduce borrowings and improve financial stability.", "News suggests a refocus on core operations after the asset sale."]
["Most analyst ratings remain Neutral, Hold, Sector Perform, or Underperform rather than Buy.", "RBC and other firms noted the stock may be fully valued or facing a high multiple.", "Mizuho and BofA both maintain Underperform ratings.", "Technical momentum is not fully confirmed, with MACD still negative.", "Pattern-based trend data suggests a 70% chance of -2.4% over the next day."]
The latest quarter referenced appears to be Q1 2026, with Q2 guidance also mentioned. RBC noted Huntsman’s Q1 results and Q2 guidance both topped estimates, and the company has been successfully implementing price increases ahead of rising raw material costs, especially benzene-linked inputs. That points to improving revenue/margin execution in the recent quarter, but the lack of full financial figures prevents a deeper assessment.
Analyst sentiment is mixed to cautious. Recent target increases from Deutsche Bank, Morgan Stanley, RBC, and Citi show improving expectations, with targets clustered around $15-$16. However, ratings are still mostly Hold/Neutral/Sector Perform, while Mizuho and BofA remain Underperform. Wall Street’s pros: better-than-expected Q1/Q2 execution, price increases, and asset-sale balance sheet support. Cons: valuation concerns, weak overall rating consensus, and not enough conviction for a clear bullish stance.
